Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any combined deficiency of factor V and factor VIII in which the cause of the disease is a mutation in the MCFD2 gene.
Features include: Reduced factor VIII activity, Menorrhagia, Reduced coagulation factor V activity, and Persistent bleeding after trauma and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Reduced coagulation factor V activity, Persistent bleeding after trauma |
MCFD2 encodes multiple coagulation factor deficiency 2, ER cargo receptor complex subunit (146 aa). The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors Highest expression in Cells Cultured fibroblasts (173.9 TPM) and Adrenal Gland (149.6 TPM).
Factor 5 and Factor VIII, combined deficiency of, 2 is caused by mutations in the MCFD2 gene on chromosome 2.
The MCFD2 protein participates in hexameric LMAN1:MCFD2, LMAN1:MCFD2:glycosylated FV, FVIII precursor, and Hexameric LMAN1:MCFD2 bind glycosylated Factor V and VIII precursors pathways.
MCFD2 is classified as a druggable target with score 0.0.
Genetic testing for MCFD2 is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for factor 5 and Factor VIII, combined deficiency of, 2.
7 publications have been identified in PubMed for factor 5 and Factor VIII, combined deficiency of, 2. Research spans Review / Meta-Analysis (43%), Case Report / Case Series (29%), and Basic Science / Preclinical (29%).
Bendarkawi Y (2025). [PMID: 40296097](https://pubmed.ncbi.nlm.nih.gov/40296097/). *J Med Case Rep*. [Case Report / Case Series]
Tourbih H (2025). [PMID: 40747195](https://pubmed.ncbi.nlm.nih.gov/40747195/). *Cureus*. [Review / Meta-Analysis]
Yakovleva E (2025). [PMID: 39209292](https://pubmed.ncbi.nlm.nih.gov/39209292/). *Semin Thromb Hemost*. [Review / Meta-Analysis]
Alhamadeh Alswij M (2025). [PMID: 41377787](https://pubmed.ncbi.nlm.nih.gov/41377787/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Solgun HA (2025). [PMID: 39757163](https://pubmed.ncbi.nlm.nih.gov/39757163/). *Ital J Pediatr*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Everett LA (2024). [PMID: 39499573](https://pubmed.ncbi.nlm.nih.gov/39499573/). *JCI Insight*. [Basic Science / Preclinical]
Ma S (2024). [PMID: 39222205](https://pubmed.ncbi.nlm.nih.gov/39222205/). *J Thromb Thrombolysis*. [Basic Science / Preclinical]